Pediatrix and Life Time post third-quarter results above analyst estimates

what happened

Pediatrix Medical Group reported third-quarter revenue of $501.374 million, against an IBES estimate of $498.1 million. Adjusted EBITDA reached $85.48 million versus expectations of $80.1 million, and net income came in at $46.991 million. The company's full-year adjusted EBITDA outlook is $290–300 million, while the IBES estimate sits at $290.2 million.

Life Time Group posted third-quarter revenue of $893.5 million, compared with the IBES estimate of $874.7 million. Adjusted EBITDA was $256.3 million against a forecast of $244.7 million, and net income was $106.5 million. Figures are from Reuters.

why it matters

Both reports came in above consensus on key profit measures, which typically supports the shares in the short term. Pediatrix's annual outlook is only slightly above its estimate, so the revision to expectations looks modest based on these numbers.

market impact

Pediatrix and Life Time shares: EBITDA above estimates supports the stocks

• ▲Life Time Group shares pressure up — revenue and adjusted EBITDA above IBES estimates
• ▲Pediatrix Medical Group shares pressure up — quarterly adjusted EBITDA above IBES estimates

tags

instruments